The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy.
 
Caroline Weipert
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Foundation Medicine
 
Jennifer Saam
Employment - Guardant Health; Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; IDbyDNA; Soluventis
Honoraria - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
Consulting or Advisory Role - Actuate Therapeutics; Gaido; Loxo; Merck; NeoMed; Pfizer; Roche; Soluventis; XBiotech
Speakers' Bureau - Roche
Research Funding - Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley